Notice of AGM and Directorate Change

LEI: 213800FLQUB9J289RU66

5 November 2018

BATM Advanced Communications Limited

("BATM" or "the Group")

Notice of AGM and Directorate Change

BATM Advanced Communications Limited (LSE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, gives notice that the Annual General Meeting ("AGM") of the Group is to be held at 10.00am GMT on Wednesday 28 November 2018 at the offices of Luther Pendragon, 48 Gracechurch Street, London, EC3V 0EJ, England.

Among the resolutions to be voted on at the AGM are the proposed appointments of Prof. Ari Shamiss and Prof. Varda Shalev as external directors of the Group, as required under Israeli law, for three-year periods commencing upon the approval of the resolution at the AGM. Prof. Shamiss and Prof. Shalev will be replacing Dr. Avigdor Shafferman and Mrs Orna Pollack respectively, whose three-year tenures as external directors expire and who retire from the Board of Directors.   

Further information on the resolutions can be found in the Notice of AGM circular that has, along with forms of proxy and direction, been posted to shareholders and is available on BATM's website at: www.batm.com.

Proposed Director Appointments

Prof. Ari Shamiss

Prof. Ari Shamiss, aged 60, is a medical expert with over 35 years' experience in the healthcare and biotechnology industries. He is currently CEO of Assuta Medical Centers, a network of eight hospitals and medical centres in Israel. Prior to assuming this position in 2016, Prof. Shamiss spent over 30 years at the Sheba Medical Center, which is the largest hospital in Israel and where a significant proportion of the country's clinical research is conducted, in various roles and most latterly being CEO of the Sheba General Hospital from 2005 to 2016.  

He has also served in advisory roles at various private and public organisations, including academic institutions such as being a Senior Lecturer at Tel Aviv University School of Medicine and a Senior Researcher at Harvard Business School. He has provided business advisory and consultancy to companies such as Quantason LLC, a California-based med-tech company that has developed a next-generation ultrasound technology, and currently BioGaming, an Israeli provider of an artificial intelligence solution to enhance physical therapy to improve rehabilitation outcomes. He also sits on the advisory board of the Sheba Cancer Research Center Council and the Gertner Institute for Epidemiology and Health Policy Research.

Prof. Varda Shalev

Prof. Varda Shalev (née Borst), aged 59, is a specialist in epidemiology, medical informatics and predictive analytics in community healthcare. She currently holds the position of Director of the Morris Kahn & Maccabi Institute for Health Research and Innovation and is an active primary care physician in Maccabi Healthcare Services in Tel Aviv, where she has worked for eight years. She has pioneered the development of multiple disease registries to support chronic disease management. In addition, she is a faculty member at the Tel Aviv University School of Public Health and sits on the advisory board of several med-tech businesses, including Belongtail Ltd, Ibex Medical Analytics Ltd, NUVO Inc and Valera Health, and is a director of the Israel Advanced Technology Industries, a non-profit organisation. She is a director and co-owner of Dr. Benjamin Shalev Eye Physician Ltd, through which she provides physician services.  

She holds an MD degree from Ben-Gurion University Medical School in Israel, and completed her residency in family medicine and earned a Master of Public Health Administration at Clark University in the US. She then completed a two-year fellowship in medical informatics at the Johns Hopkins University Hospital in the US. Prof. Shalev has authored or co-authored over 200 publications in peer-reviewed medical journals.

There is no further information required to be disclosed in relation to Prof. Shamiss or Prof. Shalev pursuant to Listing Rule 9.6.13 and neither of them has any beneficial interest in BATM's ordinary shares.

Enquiries: